Elixia LLC

1. AstraZeneca Pharmaceuticals LP $1,154,829 29 payments
2. GlaxoSmithKline, LLC. $773,060 47 payments
3. Boehringer Ingelheim Pharmaceuticals, Inc. $561,399 5 payments
4. Scpharmaceuticals Inc. $364,819 2 payments
5. Bayer HealthCare Pharmaceuticals Inc. $228,586 46 payments
6. Retrophin, Inc. $169,084 82 payments

1. A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $773,060 47 payments
2. Phase II dose finding PoCC in CKD $533,595 3 payments
3. Non-Interventional Exploratory Phase IV Single-Blind Cross-Sectional Randomised Cross-over Study Evaluating Patient Palatability and Preference of 3 Potassium Binders Sodium Polystyrene Sulphonate (SPS) or Calcium Polystyrene Sulphonate (CPS) Sodium Zirconium Cyclosilicate (Lokelmar) and Calcium Patiromer Sorbitex (Veltassar) in Patients with Chronic Kidney Disease and Hyperkalaemia (APPETIZE) $431,196 4 payments
4. Open-Label, Single-Dose, Randomized, Two-Way Two-Period Crossover Study to Compare the Pharmacokinetics and Pharmacodynamics of Scp-111 Furosemide Injection Administered As A Subcutaneous Injection VS Furosemide Administered As An Intravenous Injection $364,819 2 payments
5. Cardiovascular Renal and Metabolism Lokelma Hyperkalemia $356,222 7 payments
6. TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal $279,337 16 payments
7. 021Fsgs16010 $163,960 79 payments
8. BAY94-8862, Finerenone Phase 3 in non-diabetic CKD $153,643 26 payments
9. An Open-Label Randomized Controlled Parallel Design Multicentre Phase IV Study of Sodium Zirconium Cyclosilicate and Enhanced Nutrition Advice Compared to Standard of Care in Dialysis Patients with Hyperkalaemia GRAZE $88,074 2 payments
10. BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic $41,634 12 payments

1. Patient care $304,091 1 payment
2. Other $166,467 80 payments
3. Non-patient care $60,728 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.